Will federal legislation resolve ongoing DEA/drug-distributor conflicts?
    An indictment from the US Attorney, Northern District of California, over past practices of FedEx in mail-order drug deliveries, announced in July, has been expanded to include money laundering charges. That addition is apparently from FedEx's standard service of collecting payments on behalf of some customers; FedEx's collect on delivery service "is available to all of our millions of FedEx Express customers," Patrick Fitzgerald, a company spokesman, told the Wall Street Journal, while reiterating that FedEx disputes all the charges the Dept. of Justice
    Meanwhile, a scramble to accelerate vaccine testing ramps up
    Direct Relief, Inc., one of a number of public health nonprofits that responds to disasters and other healthcare crises, is organizing a shipment of more than 40 tons of essential medicines and supplies to support healthcare workers trying to manage the Ebola outbreak, now affecting several countries in West Africa. The death toll has passed 1,000 (and is thought to be significantly undercounted) and the latest reports from the World Health Organisation say that it could last months. This latest shipment from Direct Relief (there has been at least one prior delivery) includes 2.3 million gloves, 65,000 masks, 92,000 gowns, and 185,000 tabs of antibiotics
    Three times as many manufacturers expect more 3PL use as expect less; 38% see no change
    A survey conducted by Sonoco ThermoSafe, one of the leading providers of passive packaging for life sciences products, shows that industry managers place performance above cost as a container-selection qualification, are looking to increase their usage of third-party logistics (3PLs) providers, and are increasingly factoring in environmental concerns with recyclability and reuse of the containers. Preliminary results are based on 165 respondents both who were both personally interviewed and who filled out an online survey. Pharmaceutical Commerce's editor in chief, Nick Basta, was part of
    Postponement of public data for six months is justified by slow rollout of CMS rules, they say
    The pharma industry, among other life sciences firms, has been busy for most of this year preparing its reports to CMS on payments made to prescribers and some of their hospital affiliations. But over on the physicians' side, near-panic seems to be setting in as the Sept. 30 date for public release of the spending data approaches. A letter (available here; registration required) has been sent to Marilyn Tavenner, CMS Administrator, seeking a six-month publication delay as required by the Open Payments System established under the Physician Payments Sunshine Act. For industry, the challenge is to properly aggregate
    Outsourced contract-administration provider highlights growth in invoicing and financial stewardship burdens
    It's no secret that managing the basic billing, payment collection and reconciliation of the pharma industry is more complicated today. Even before Obamacare (which is expanding both the number and complexity of billing entities), pharma finance departments were dealing with a bewildering array of federal and state programs, and more complicated fee-and-chargeback arrangements with wholesalers. Add to this the variety of patient-support programs, analysis of coupon programs and other financial arrangements, and the overall picture becomes ever more obscure. Nor should the trend toward more--and bigger--
    First to gain newly established program reviewing therapy management and chronic care
    CVS/pharmacy, the Woonsocket, RI, chain with over 7,600 stores nationally, has been granted the first "community pharmacy" accreditation granted by URAC (Washington, DC). URAC, in turn, is a standards-setting body for healthcare providers, pharmacies and other parts of healthcare delivery. Its standards, which have legal status with federal programs and most states, validate quality systems, recordkeeping and other functions; it "is a symbol of excellence for organizations to validate their commitment to quality and accountability," according
    Adds drug development services to its clinical, commercial packaging
    Packaging Coordinators, Inc. (Philadelphia), which started with the contract packaging operations of Cardinal Health and then picked up the same from AmerisourceBergen just over a year ago, has now added Penn Pharma (Tredegar, Wales) to its portfolio. While PCI's core business is mostly commercial contract packaging (it recently began adding capabilities for clinical trial product supply and services), Penn Pharma brings both drug development and clinical trial services to the mix. If the company hasn't become a full-blown contract development and manufacturing organization (CDMO) already
    Latest ZS AccessMonitor asks, 'Who are [physicians] listening to?'
    The annual update from ZS Associates (Chicago), a consulting firm on sales and related practices in life sciences, finds that 51% of physicians were considered "accessible" this year, as compared to 55% in 2013. "Though this year's drop was less precipitous than in previous years, it reflects the steady decline in access over the past decade," concludes the report. Data are based on call reports for over 200 pharma sales teams, meeting with approximately 325,000 prescribers. "Accessible" means those who were not either "access restricted" (who met with 31-70% of the reps who called on them) or
    After patent expiries, 'The industry has turned a corner'
    The World Preview 2014 from Evaluate Pharma (US HQ: Boston) totes up current worldwide pharma sales, assesses pipeline products, and projects industry growth to 2020. According to Paul Hills, head of operations, the "quality" (i.e., projected market value) of new drugs approved by FDA in 2013 increased by 43% over the previous year; this marks a "step change in innovation and output for the industry since 2009." Nine of the top ten introduced that year (led by Gilead Science's Sovaldi) will
    Pharmaceutical Commerce's latest report finds continued growth in these specialized logistics services
    The 5th edition of the Biopharma Cold Chain Sourcebook analyzes economic, regulatory and technological trends in a vital part of today's industry: the shipment of temperature-controlled products. The just-published report calculates that current (2014) expenditures for commercial shipments will be $8.36 billion, rising to $10.28 billion in 2018. By comparison, last year's Sourcebook estimated the 2013 cold-chain business to be $7.5 billion, rising
Pharmaceutical Commerce
Digital Edition
Current Digital Edition
Read the July/August 2014 Issue now - It's Free!
Family of GTS Carry Packs handles drugs that patients self-administer
August 23-26, 2014
September 3-5, 2014
September 8-10, 2014
September 14-17, 2014
September 16-18, 2014
September 29 - October 3, 2014
Pharmaceutical Commerce sat down with Angela Miccoli, president of Cegedin Relationship Management NA, to talk about sales force automation, customer relationship management and multichannel marketing. Here’s what she had to say.
The eye-popping price tag on the hepatitis C drug, from Gilead Sciences, has prompted unprecedented pushback from payers  continued >
How to prepare for reporting and utilizing published data for business and compliance purposes  continued >
Setting a foundation for long-term success: How the pharmaceutical industry can transform Big Data into actionable insight  continued >
Global industry will spend $8.36 billion on cold chain logistics this year  continued >
A rising flow of new, expensive therapies is transforming relationships among payers and providers. Manufacturers will have to react nimbly to the changes  continued >
US pharma layoffs do not reflect the industry's health
The perverse fascination that the business press has with pharma layoffs masks the industry's underlying strength
  |     |     |     |     |     |  
©2014 Pharmaceutical Commerce. All Rights Reserved.  |  Website managed and designed by Offenberger & White.